Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 RON | +1.20% | +6.29% | +15.75% |
1st Jan change | Capi. | |
---|---|---|
+15.75% | 505M | |
+20.70% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+12.11% | 13.64B | |
+39.64% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology